

Pilar Rivera-Ortega

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6205080/pilar-rivera-ortega-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

1,658
citations

9
h-index

39
g-index

39
ext. papers

2,938
ext. citations

12.8
avg, IF

3.9
L-index

#	Paper	IF	Citations
20	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1275-1287	35.1	58
19	Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity. <i>Archivos De Bronconeumologia</i> , 2021 , 58, 135-135	0.7	1
18	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 1637-1645	40	537
17	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 2049-2059	40	157
16	Smoking cessation: strategies and effects in primary and secondary cardiovascular prevention. <i>Panminerva Medica</i> , 2021 , 63, 110-121	2	2
15	Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. <i>Advances in Therapy</i> , 2021 , 38, 4505-4519	4.1	3
14	Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers. <i>Respirology</i> , 2021 , 26, 352-359	3.6	8
13	Reply to Althwaybi : Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 522-524	10.2	
12	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021 , 397, 605-612	40	117
11	An update on interstitial lung disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021 , 82, 1-14	0.8	0
10	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6	6
9	Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 231-233	1.1	1
8	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1656-1665	10.2	72
7	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2030-2040	59.2	628
6	Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD. <i>International Journal of COPD</i> , 2020 , 15, 1823-1829	3	0
5	The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. <i>ERJ Open Research</i> , 2019 , 5,	3.5	24
4	Trabecular bone score in active or former smokers with and without COPD. <i>PLoS ONE</i> , 2019 , 14, e0209777	3.7	3

3	Interstitial Lung Diseases in Developing Countries. <i>Annals of Global Health</i> , 2019 , 85,	3-3	10
2	Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018 , 12, 1753466618800618	4-9	27
1	Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.		3